Russ at UF
@rthepple.bsky.social
Scientist, lifelong athlete, home cook, music lover and amateur musician, husband, father, brother, son. Research interests: aging, cancer cachexia, sepsis, skeletal muscle and mitochondria. Did I mention mitochondria?
We should also have one for Canadian scientists in US. Stronger together regardless of borders. You know, the way it was before all this 51st state rhetoric. For the record, I love my American colleagues (that’s why I moved here) and think the current situation is an insult to us all.
March 22, 2025 at 9:51 PM
We should also have one for Canadian scientists in US. Stronger together regardless of borders. You know, the way it was before all this 51st state rhetoric. For the record, I love my American colleagues (that’s why I moved here) and think the current situation is an insult to us all.
Absolutely beautiful work.
March 22, 2025 at 9:41 PM
Absolutely beautiful work.
Thanks to @droch.bsky.social for correction - this should be Novo Nordisk not Roche
March 22, 2025 at 9:35 PM
Thanks to @droch.bsky.social for correction - this should be Novo Nordisk not Roche
Thanks Julien. I questioned this after I hit send and was going to try to edit.
March 22, 2025 at 4:16 PM
Thanks Julien. I questioned this after I hit send and was going to try to edit.
But I think your statement only applies if academia generates a compound because a process or pathway cannot be patented and any returns on compound go to university not NIH. I was thinking of what happens with Roche in Denmark but I am not versed in roadblocks here in US
March 22, 2025 at 3:44 PM
But I think your statement only applies if academia generates a compound because a process or pathway cannot be patented and any returns on compound go to university not NIH. I was thinking of what happens with Roche in Denmark but I am not versed in roadblocks here in US
Begging the question of why it is not mandated that a return of a percentage of profits on said drugs go back to fund NIH research.
March 22, 2025 at 12:53 PM
Begging the question of why it is not mandated that a return of a percentage of profits on said drugs go back to fund NIH research.
Congratulations Kevin!
March 18, 2025 at 11:43 AM
Congratulations Kevin!
I wonder how specific this may be to ALS? Aging also causes Tdp43 dysfunction (risk of ALS increases w age) www.nature.com/articles/s42... so perhaps this is more about importance of CoxIV to motoneuron survival than ALS per se?
Age-related demethylation of the TDP-43 autoregulatory region in the human motor cortex - Communications Biology
In order to assess the effects of aging on the autoregulation of TAR DNA-binding protein 43 (TDP-43) and the potential effects of this on the role of TDP-43 in Amyotrophic Lateral Sclerosis (ALS), Koi...
www.nature.com
March 15, 2025 at 7:06 PM
I wonder how specific this may be to ALS? Aging also causes Tdp43 dysfunction (risk of ALS increases w age) www.nature.com/articles/s42... so perhaps this is more about importance of CoxIV to motoneuron survival than ALS per se?
Please congratulate Casper and rest of your team for me!
March 12, 2025 at 11:47 AM
Please congratulate Casper and rest of your team for me!
Reposted by Russ at UF
... gait speed. Still better than anything molecular biomarkers can provide. Our commentary (with @regula-furrer.bsky.social @biozentrum.unibas.ch @unibas.ch) out now in NPJ Aging:
doi.org/10.1038/s415...
3/3
doi.org/10.1038/s415...
3/3
Biomarkers of aging: functional aspects still trump molecular parameters - npj Aging
Biomarkers of aging are indispensable for testing interventions. While promising, the recent focus on molecular aspects should not detract from the functional parameters for which excellent correlatio...
doi.org
March 3, 2025 at 2:15 PM
... gait speed. Still better than anything molecular biomarkers can provide. Our commentary (with @regula-furrer.bsky.social @biozentrum.unibas.ch @unibas.ch) out now in NPJ Aging:
doi.org/10.1038/s415...
3/3
doi.org/10.1038/s415...
3/3
Just drop me a line, Vincent! Gilles knows how to reach me.
February 21, 2025 at 8:36 PM
Just drop me a line, Vincent! Gilles knows how to reach me.
We should try to partner with MoTrPAc to get comparator data on younger participants. Just a thought.
February 15, 2025 at 2:32 PM
We should try to partner with MoTrPAc to get comparator data on younger participants. Just a thought.
Sounds like a plan! I think an important component will be to address heterogeneity. My sense is that some will be responsive and others not so much.
February 15, 2025 at 2:31 PM
Sounds like a plan! I think an important component will be to address heterogeneity. My sense is that some will be responsive and others not so much.
It is this period when preservation of oxphos might become the cause of greater voluntary exercise rather than the result. Let’s call it a hypothesis 😊
February 13, 2025 at 10:38 PM
It is this period when preservation of oxphos might become the cause of greater voluntary exercise rather than the result. Let’s call it a hypothesis 😊
Thanks for the very thoughtful reply, Gilles! I have no issue about exercise increasing oxphos except to make the point that I am not aware of any data addressing those >75 y, a time when the anabolic response to strength training is lost. pubmed.ncbi.nlm.nih.gov/18448613/
Single muscle fiber adaptations to resistance training in old (>80 yr) men: evidence for limited skeletal muscle plasticity - PubMed
The purpose of this study was to investigate whole muscle and single muscle fiber adaptations in very old men in response to progressive resistance training (PRT). Six healthy independently living old...
pubmed.ncbi.nlm.nih.gov
February 13, 2025 at 10:35 PM
Thanks for the very thoughtful reply, Gilles! I have no issue about exercise increasing oxphos except to make the point that I am not aware of any data addressing those >75 y, a time when the anabolic response to strength training is lost. pubmed.ncbi.nlm.nih.gov/18448613/